Markets:

Overview

News

Currencies

International

Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

3.520 +0.180 (+5.39%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

2 Beaten-Down Artificial Intelligence (AI) Stocks for Contrarian Investors to Consider Buying ↗

Today 0:35 EDT

These aren't for the faint of heart.

Via The Motley Fool

Topics Artificial Intelligence

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? ↗

June 02, 2026

Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.

Via The Motley Fool

Topics Artificial Intelligence

Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗

May 25, 2026

The stock looks cheap, but appearances can be deceiving.

Via The Motley Fool

Topics Artificial Intelligence

Recursion Pharmaceuticals (RXRX) Q1 2026 Results: Revenue Miss Overshadows Narrower Net Loss ↗

May 06, 2026

Via Chartmill

Recursion Pharmaceuticals (NASDAQ:RXRX) Soars on Q4 Earnings Beat ↗

February 25, 2026

Via Chartmill

A Deep Dive Into NVIDIA’s Latest Portfolio Moves ↗

May 19, 2026

NVIDIA's latest 13F filing does not tell the story it seems to at first glance. The apparent divergence in its CoreWeave and Nebius holdings is a prime example.

Via MarketBeat

Topics Artificial Intelligence Economy Regulatory Compliance

3 Stocks Poised to Disrupt the Healthcare Market by 2030 ↗

May 08, 2026

The old healthcare model is breaking down.

Via The Motley Fool

Topics Artificial Intelligence

Recursion (RXRX) Q1 2026 Earnings Transcript ↗

May 07, 2026

Recursion (RXRX) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Artificial Intelligence

Lilly’s $47.8 Billion Bet: Why the Contessa Acquisition Redefines the Future of Medicine

April 06, 2026

In a move that has sent shockwaves through both the pharmaceutical and technology sectors, Eli Lilly and Company (NYSE: LLY) announced today, April 6, 2026, the finalized acquisition of Contessa, a...

Via MarketMinute

Topics Artificial Intelligence

1 Beaten-Down AI Stock to Buy and 1 to Avoid ↗

April 01, 2026

One of these is not like the other.

Via The Motley Fool

Topics Artificial Intelligence

2 AI Healthcare Stocks to Buy Right Now ↗

March 31, 2026

The convergence of two already fantastic industries is creating an incredible opportunity.

Via The Motley Fool

Topics Artificial Intelligence

Prediction: The "Trough of Disillusionment" Will Create the Best Buying Opportunity for Artificial Intelligence (AI) Stocks in 2026 ↗

March 22, 2026

The sweeping correction that most of these stocks have suffered was not only predictable, but it also reliably precedes a better-supported recovery.

Via The Motley Fool

Topics Artificial Intelligence

Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years. ↗

March 21, 2026

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.

Via The Motley Fool

Topics Artificial Intelligence

Can This AI Stock Bounce Back in 2026? ↗

March 08, 2026

It's not looking too good for the biotech.

Via The Motley Fool

Topics Animal Testing Artificial Intelligence

Recursion (RXRX) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Recursion (RXRX) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Artificial Intelligence Earnings

What's Behind The Jump In Recursion Pharmaceuticals Stock? ↗

February 25, 2026

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) are surging Wednesday following a robust earnings report released before the bell.

Via Benzinga

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗

February 25, 2026

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

Via Stocktwits

Topics Artificial Intelligence

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

February 22, 2026

Ark Invest added to three positions that are well below last year's highs.

Via The Motley Fool

Topics Artificial Intelligence

NVIDIA’s 13F Bombshell: A New AI Power Trio Emerges ↗

February 19, 2026

Via MarketBeat

Topics Artificial Intelligence

Recursion Pharmaceuticals Stock Drops: What's Behind It? ↗

February 18, 2026

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp (NASDAQ:NVDA) has fully exited its investment in the AI‑focused...

Via Benzinga

The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot

February 17, 2026

As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a...

Via MarketMinute

Topics Artificial Intelligence Economy Initial Public Offering

This $4 Stock Could Be Your Ticket to Millionaire Status ↗

February 07, 2026

It's a potential game-changing technology. The company just needs to prove to the world that it works well enough.

Via The Motley Fool

Topics Artificial Intelligence

Harvard’s PopEVE AI Cracks the Code of Rare Diseases: Ending the ‘Diagnostic Odyssey’ for Millions

February 06, 2026

In a landmark achievement for computational biology, researchers from Harvard Medical School and the Centre for Genomic Regulation (CRG) have unveiled PopEVE, a groundbreaking artificial intelligence...

Via TokenRing AI

Topics Artificial Intelligence

AI’s ‘Penicillin Moment’: How Generative Models Are Slashing Decades of Antibiotic Research into Months

February 06, 2026

In a breakthrough that many are calling the "Penicillin Moment" of the 21st century, researchers at the Massachusetts Institute of Technology, led by bioengineering pioneer James Collins, have...

Via TokenRing AI

Topics Artificial Intelligence

Forget 2025: These 2 Growth Stocks Could Soar in 2026 ↗

January 29, 2026

Last year's weakness is ultimately an improved entry opportunity for long-term-minded investors.

Via The Motley Fool

Can This Beaten-Down AI Stock Bounce Back in 2026? ↗

January 28, 2026

It might take a while for this AI company to prove its worth, if it ever does so.

Via The Motley Fool

Topics Artificial Intelligence

2 AI Stocks to Buy in 2026, and 1 to Avoid ↗

January 16, 2026

Some AI-focused companies are not worth the trouble.

Via The Motley Fool

Topics Artificial Intelligence

Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution

January 12, 2026

In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"...

Via TokenRing AI

Topics Artificial Intelligence

From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance

January 12, 2026

In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis

January 01, 2026

In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position...

Via TokenRing AI

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.